September 2018 – August 2019, Diamyd Medical AB (publ), Fiscal year 2018/2019
To preserve and regain the body’s own insulin production
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.
Further information is available on https://www.diamyd.com
Figures in parentheses relate to the corresponding period previous financial year.
September 1, 2018 – August 31, 2019
· Net income: MSEK 1.6 (0.8), whereof the fourth quarter MSEK 0.3 (0.1). The change refers to increased sales of GAD-protein for pre-clinical research.
· Net result: MSEK –
Source: Year-End Report 18/19